Virpax Pharmaceuticals is focused on developing innovative drug delivery technologies aimed at addressing pain management and central nervous system (CNS) disorders. Their flagship product, Probudur, utilizes proprietary liposomal encapsulation to provide sustained release of bupivacaine, a local anesthetic, which has shown the potential to manage post-operative pain for up to 96 hours following a single injection. This technology not only aims to enhance patient comfort but also seeks to reduce reliance on opioids, thereby addressing the growing concerns surrounding opioid addiction and side effects. The company collaborates with esteemed institutions, including the National Institutes of Health and the U.S. Army Institute of Surgical Research, to further develop these non-addictive treatment options.

In addition to Probudur, Virpax is advancing other products such as Envelta and NobrXiol, which leverage their Molecular Envelope Technology (MET) for targeted drug delivery. Envelta is an intranasal formulation of enkephalin designed to control severe pain without the respiratory depression associated with traditional opioids, while NobrXiol is a pharmaceutical-grade cannabidiol (CBD) product aimed at managing rare pediatric epilepsy. Both products utilize MET to enhance drug bioavailability and facilitate direct delivery to the brain, bypassing the blood-brain barrier and minimizing potential drug interactions. Through these innovative platforms, Virpax Pharmaceuticals is committed to addressing unmet medical needs in pain management and CNS disorders.

United States

Virpax Pharmaceuticals specializes in developing novel and proprietary drug delivery systems

Virpax Pharmaceuticals

Company Details